Gilead Sciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript - Seeking Alpha
Posted by admin / Under Gear Acquisition Syndrome
Gilead Sciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript Seeking Alpha In keeping with our philosophy to develop best-in-class drugs, we acquired Pharmasset in order to bring PSI-7977 to our portfolio. We anticipate that we will be able to conduct and complete the clinical study and to allow the first approval of 7977 in ... |
Published on Saturday 11th of February 2012 10:43:21 AM
Share this!